First-on-line results for As and F beams from HRIBF target/ion sources (vol 126, pg 166, 1997)

被引：0
|
作者：
Carter, HK [1 ]
Kormicki, J
Stracener, DW
Breitenbach, JB
Guber, KH
Blackmon, JC
Smith, MS
Bardayan, DW
机构：
[1] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37831 USA
[2] Univ N Carolina, Chapel Hill, NC 27599 USA
[3] Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA
[4] Yale Univ, AW Wright Nucl Struct Lab, New Haven, CT 06511 USA
[5] Vanderbilt Univ, Dept Phys, Nashville, TN 37235 USA
来源：
NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM INTERACTIONS WITH MATERIALS AND ATOMS | 1999年 / 149卷 / 03期
关键词：
D O I：
暂无
中图分类号：
TH7 [仪器、仪表];
学科分类号：
0804 ; 080401 ; 081102 ;
摘要：
引用
收藏
页码：368 / 368
页数：1
相关论文
共 13 条
  • [1] First on-line results for As and F beams from HRIBF target/ion sources
    Carter, H.K.
    Kormicki, J.
    Stracener, D.W.
    Breitenbach, J.B.
    Blackmon, J.C.
    Smith, M.S.
    Bardayan, D.W.
    Nuclear Instruments and Methods in Physics Research, Section B: Beam Interactions with Materials and Atoms, 1997, 126 (1-4): : 166 - 169
  • [2] First on-line results for As and F beams from HRIBF target/ion sources
    Carter, HK
    Kormicki, J
    Stracener, DW
    Breitenbach, JB
    Blackmon, JC
    Smith, MS
    Bardayan, DW
    NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B-BEAM INTERACTIONS WITH MATERIALS AND ATOMS, 1997, 126 (1-4): : 166 - 169
  • [3] First on-line results for As and F beams from HRIBF target/ions sources
    Stracener, DW
    Carter, HK
    Kormicki, J
    Breitenbach, JB
    Blackmon, JC
    Smith, MS
    Bardayan, DW
    APPLICATION OF ACCELERATORS IN RESEARCH AND INDUSTRY - PROCEEDINGS OF THE FOURTEENTH INTERNATIONAL CONFERENCE, PTS 1 AND 2, 1997, (392): : 393 - 396
  • [4] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study (vol 81, pg 17, 2017)
    Chau, Ian
    Peck-Radosavljevic, Markus
    Borg, Christophe
    Malfertheiner, Peter
    Seitz, Jean Francois
    Park, Joon Oh
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Kudo, Masatoshi
    Poon, Ronnie
    Pastorelli, Davide
    Blanc, Jean-Frederic
    Chung, Hyun Cheol
    Baron, Ari D.
    Okusaka, Takuji
    Bowman, L.
    Cui, Zhanglin Lin
    Girvan, Allicia C.
    Abada, Paolo B.
    Yang, Ling
    Zhu, Andrew X.
    EUROPEAN JOURNAL OF CANCER, 2018, 100 : 135 - 136
  • [5] Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study (vol 130, pg 216, 2019)
    Steffens, Claus-Christoph
    Elender, Corinna
    Hutzschenreuter, Ulrich
    Dille, Stephanie
    Binninger, Adrian
    Spring, Lisa
    Jaenicke, Martina
    Marschner, Norbert
    LUNG CANCER, 2019, 135 : 236 - 236
  • [6] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2019, 20 (10): : E559 - E559
  • [7] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2020, 21 (11): : E518 - E518
  • [8] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2020, 21 (06): : E304 - E304
  • [9] Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (vol 189, pg 689, 2021)
    De Laurentiis, Michelino
    Borstnar, Simona
    Campone, Mario
    Warner, Ellen
    Bofill, Javier Salvador
    Jacot, William
    Dent, Susan
    Martin, Miguel
    Ring, Alistair
    Cottu, Paul
    Lu, Janice
    Ciruelos, Eva
    Azim, Hamdy A.
    Chatterjee, Sanjoy
    Zhou, Katie
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Zamagni, Claudio
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (01) : 223 - 224
  • [10] Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study (vol 30, pg 2046, 2012)
    Lynch, T. J.
    Bondarenko, I
    Luft, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3654 - 3654
12